Latest filing published 07 Jul 2026 for BioCardia, Inc., €19k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Edward M. Gillis (chief executive) discloses dealings in BioCardia, Inc. to SEC (Form 4). Over a trading history stretching from 10 June 2021 to 2 July 2026, the count stands at 10 filings.
The open-market record consists of 1 sale worth €6,285, with no purchase. Outside the open market, there are 9 share grants.
The record was last updated on 7 July 2026 with a share grant (€19k) in BioCardia, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations